Literature DB >> 27417586

Functional Variant in the SLC22A3-LPAL2-LPA Gene Cluster Contributes to the Severity of Coronary Artery Disease.

Long Wang1, Juan Chen1, Ying Zeng1, Jie Wei1, Jinjin Jing1, Ge Li1, Li Su1, Xiaojun Tang1, Tangchun Wu1, Li Zhou2.   

Abstract

OBJECTIVE: Recent genome-wide association studies have identified that genetic variants in the SLC22A3-LPAL2-LPA gene cluster influence plasma lipoprotein(a) [Lp(a)] concentration. However, the association between this gene cluster and the severity of coronary artery disease (CAD), especially the potential underlying mechanism, remains unclear. The purpose of this study was to investigate the association between variation in the SLC22A3-LPAL2-LPA gene cluster and CAD. APPROACH AND
RESULTS: We performed 2-stage case-control studies in a Chinese Han population. The variant genotypes were examined for their association with both Lp(a) level and severity of CAD. Putative mechanisms were also evaluated. One single nucleotide polymorphism, rs3088442, in the SLC22A3-LPAL2-LPA gene cluster was significantly associated with both plasma Lp(a) levels and CAD severity. The gene dosage of the risk allele at rs3088442 indicated a robust association with left main trunk disease (P=0.046), number of vascular lesions (P=4.5×10(-3)), and Gensini scores (P=0.012) in patients with CAD. Reporter gene analysis indicated that the rs3088442 G allele might suppress miR-147a binding to the 3' untranslated region of SLC22A3, resulting in altered SLC22A3 and LPA gene expression (P=0.015 and 9.2×10(-6), respectively), possibly explaining the increased plasma Lp(a) levels and risk of CAD.
CONCLUSIONS: The genotype of rs3088442 within the SLC22A3-LPAL2-LPA gene cluster may contribute to regulation of plasma Lp(a) levels and possibly to the severity of CAD in a Chinese Han population.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  SLC22A3-LPAL2-LPA; coronary artery disease; genome-wide association study; severity; single nucleotide polymorphism

Mesh:

Substances:

Year:  2016        PMID: 27417586     DOI: 10.1161/ATVBAHA.116.307311

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  7 in total

1.  Emerging Roles of the Human Solute Carrier 22 Family.

Authors:  Sook Wah Yee; Kathleen M Giacomini
Journal:  Drug Metab Dispos       Date:  2021-12-17       Impact factor: 3.579

2.  Targeting OCT3 attenuates doxorubicin-induced cardiac injury.

Authors:  Kevin M Huang; Megan Zavorka Thomas; Tarek Magdy; Eric D Eisenmann; Muhammad Erfan Uddin; Duncan F DiGiacomo; Alexander Pan; Markus Keiser; Marcus Otter; Sherry H Xia; Yang Li; Yan Jin; Qiang Fu; Alice A Gibson; Ingrid M Bonilla; Cynthia A Carnes; Kara N Corps; Vincenzo Coppola; Sakima A Smith; Daniel Addison; Anne T Nies; Ralf Bundschuh; Taosheng Chen; Maryam B Lustberg; Joanne Wang; Stefan Oswald; Moray J Campbell; Pearlly S Yan; Sharyn D Baker; Shuiying Hu; Paul W Burridge; Alex Sparreboom
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-02       Impact factor: 11.205

3.  High Throughput Screening of a Prescription Drug Library for Inhibitors of Organic Cation Transporter 3, OCT3.

Authors:  Eugene C Chen; Pär Matsson; Mina Azimi; Xujia Zhou; Niklas Handin; Sook Wah Yee; Per Artursson; Kathleen M Giacomini
Journal:  Pharm Res       Date:  2022-01-28       Impact factor: 4.580

4.  PARP-1 Variant Rs1136410 Confers Protection against Coronary Artery Disease in a Chinese Han Population: A Two-Stage Case-Control Study Involving 5643 Subjects.

Authors:  Xue-Bin Wang; Ning-Hua Cui; Shuai Zhang; Shu-Ren Guo; Ze-Jin Liu; Liang Ming
Journal:  Front Physiol       Date:  2017-11-14       Impact factor: 4.566

5.  Elevated lipoprotein (a) levels are associated with the acute myocardial infarction in patients with normal low-density lipoprotein cholesterol levels.

Authors:  Gaojun Cai; Zhiying Huang; Bifeng Zhang; Lei Yu; Li Li
Journal:  Biosci Rep       Date:  2019-04-05       Impact factor: 3.840

6.  LPAL2 Suppresses Tumor Growth and Metastasis of Hepatocellular Carcinoma by Modulating MMP9 Expression.

Authors:  Yang-Hsiang Lin; Yu-Chin Liu; Cheng-Yi Chen; Hsiang-Cheng Chi; Meng-Han Wu; Po-Shuan Huang; Cheng-Chih Chang; Tzu-Kang Lin; Chau-Ting Yeh; Kwang-Huei Lin
Journal:  Cells       Date:  2022-08-22       Impact factor: 7.666

7.  Solute Carrier Transportome in Chemotherapy-Induced Adverse Drug Reactions.

Authors:  Jason T Anderson; Kevin M Huang; Maryam B Lustberg; Alex Sparreboom; Shuiying Hu
Journal:  Rev Physiol Biochem Pharmacol       Date:  2022       Impact factor: 7.500

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.